BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kynamro mipomersen regulatory update

Isis said partner Genzyme Corp. will delay submission of an NDA to FDA for Kynamro mipomersen to treat homozygous familial hypercholesterolemia (hoFH) to...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >